Cytokine-informed single-cell and bulk transcriptomics refine risk stratification and identify TBX19 as a prioritized candidate in colorectal cancer

Immune checkpoint blockade (ICB) has improved the treatment of mismatch repair-deficient (dMMR) and microsatellite instability-high (MSI-H) colorectal cancer (CRC), but the tumor-cell programs that link response, cytokine signaling, and clinical outcome remain incompletely defined. We integrated a single-cell anti-programmed death 1 (PD-1) CRC cohort with bulk transcriptomic datasets to derive a cytokine-related immunotherapy response-associated gene set (CIBG) from response-associated signals and cytokine-pathway genes. The 39-gene signature was higher in non-responders and showed potential survival associations and immune remodeling in bulk CRC cohorts. In malignant epithelial cells, high CIBG activity marked an inflammatory state with NF-κB/TNF-α pathway activity, chemokine signaling, cytokine-response programs, and altered tumor functional scores. Inferred secreted-signaling analysis linked CIBG-high malignant cells with CXCL-, GDF-, and ANNEXIN-related interactions involving endothelial, fibroblast, and myeloid compartments. Projection of CIBG-high malignant cell genes into bulk tumors resolved two molecular subtypes with distinct clinical and transcriptional features and potential survival associations, consensus molecular subtype composition, immune-response prediction, checkpoint expression, pathway activity, and tumor microenvironment structure. Within the subtype with poorer outcome, TBX19 showed the most consistent risk association across survival analyses. TBX19 was increased in tumor tissues and differed across pathological stages. It was associated with stromal and invasion-related transcriptional features. In SW480 and HCT116 cells, shRNA-mediated TBX19 knockdown reduced TBX19 mRNA and protein expression and reduced proliferation, migration, and wound closure. These data support a cytokine-informed transcriptomic approach to CRC stratification and identify TBX19 as a prioritized prognostic candidate.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-17
DOI
https://doi.org/10.3389/fimmu.2026.1999796
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cytokine-informed single-cell and bulk transcriptomics refine risk stratification and identify TBX19 as a prioritized candidate in colorectal cancer

Anpeng Ran, Jingyuan Ning, Shuyuan ZHAO, Jingkun Liu et al.
2 links
Frontiers in Immunology
Cancer Immunotherapy and Biomarkers
article

Cytokine-informed single-cell and bulk transcriptomics refine risk stratification and identify TBX19 as a prioritized candidate in colorectal cancer

Anpeng Ran, Jingyuan Ning, Shuyuan ZHAO, Jingkun Liu, Junhui Li, Haifeng Wang
article en

Abstract

Immune checkpoint blockade (ICB) has improved the treatment of mismatch repair-deficient (dMMR) and microsatellite instability-high (MSI-H) colorectal cancer (CRC), but the tumor-cell programs that link response, cytokine signaling, and clinical outcome remain incompletely defined. We integrated a single-cell anti-programmed death 1 (PD-1) CRC cohort with bulk transcriptomic datasets to derive a cytokine-related immunotherapy response-associated gene set (CIBG) from response-associated signals and cytokine-pathway genes. The 39-gene signature was higher in non-responders and showed potential survival associations and immune remodeling in bulk CRC cohorts. In malignant epithelial cells, high CIBG activity marked an inflammatory state with NF-κB/TNF-α pathway activity, chemokine signaling, cytokine-response programs, and altered tumor functional scores. Inferred secreted-signaling analysis linked CIBG-high malignant cells with CXCL-, GDF-, and ANNEXIN-related interactions involving endothelial, fibroblast, and myeloid compartments. Projection of CIBG-high malignant cell genes into bulk tumors resolved two molecular subtypes with distinct clinical and transcriptional features and potential survival associations, consensus molecular subtype composition, immune-response prediction, checkpoint expression, pathway activity, and tumor microenvironment structure. Within the subtype with poorer outcome, TBX19 showed the most consistent risk association across survival analyses. TBX19 was increased in tumor tissues and differed across pathological stages. It was associated with stromal and invasion-related transcriptional features. In SW480 and HCT116 cells, shRNA-mediated TBX19 knockdown reduced TBX19 mRNA and protein expression and reduced proliferation, migration, and wound closure. These data support a cytokine-informed transcriptomic approach to CRC stratification and identify TBX19 as a prioritized prognostic candidate.

Frontiers in ImmunologyVol. 17
Hebei Medical University (CN), Xinjiang Medical University (CN), Tumor Hospital of Xinjiang Medical University (CN)
Natural Science Foundation of Xinjiang Province, Xinjiang Medical University
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon